Patents by Inventor Andre Ziegler

Andre Ziegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210239712
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 5, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210215716
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 15, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Peter Kastner, Manuel Dietrich, André Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Ulrich Schotten
  • Patent number: 11047866
    Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 29, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20210190801
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 24, 2021
    Inventors: Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Manuel Dietrich, Andre Ziegler, Ulrich Schotten
  • Publication number: 20210181211
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 17, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210172962
    Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 10, 2021
    Inventors: Manuel Dietrich, Peter Kastner, Vinzent Rolny, Ulrich Schotten, Ursula-Henrike Wienhues-Thelen, Andre Ziegler
  • Publication number: 20210156875
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
  • Publication number: 20200300869
    Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 24, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Johann Karl, Peter Kastner, Vinzent Rolny, Andre Ziegler, David Conen
  • Publication number: 20200116708
    Abstract: Disclosed is a method for diagnosing paroxysmal atrial fibrillation in a subject, involving: determining the amount of FABP-3 (Fatty acid binding protein 3) in a sample from a subject suspected to suffer from paroxysmal atrial fibrillation, and comparing the determined amount to a reference amount. The method may further involve the determination of a BNP-type peptide. Also disclosed is a device adapted to carry out the method.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Manuel Dietrich, Andre Ziegler, Ulrich Schotten
  • Publication number: 20190353666
    Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera
  • Publication number: 20190277861
    Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20190279770
    Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 12, 2019
    Applicants: Roche Diagnostics Operations, Inc., Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu
    Inventors: Dirk Block, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Faiez Zannad, Patrick Rossignol
  • Patent number: 10345315
    Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 9, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20190162737
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: February 1, 2019
    Publication date: May 30, 2019
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Ulrich Schotten, Vinzent Rolny
  • Publication number: 20190154706
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 23, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Patent number: 10231639
    Abstract: The present invention relates to a method of diagnosing whether a subject with no known history of atrial fibrillation is suffering from atrial fibrillation, or not, said method comprising the steps of a) determining the amount of a BNP-type peptide in a sample of said subject; b) comparing the amount the BNP-type peptide to a reference, and c) assessing intermittent ECG recordings obtained from said subject over a period of at least one week by using a handheld ECG device.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Mathias Emil Egermark, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Marten Rosenquist, Viveka Frykmann-Kull, Emma Svennberg, Leif Friberg
  • Patent number: 10234464
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20170296078
    Abstract: The present invention relates to a method of diagnosing whether a subject with no known history of atrial fibrillation is suffering from atrial fibrillation, or not, said method comprising the steps of a) determining the amount of a BNP-type peptide in a sample of said subject; b) comparing the amount the BNP-type peptide to a reference, and c) assessing intermittent ECG recordings obtained from said subject over a period of at least one week by using a handheld ECG device.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 19, 2017
    Inventors: Mathias Emil Egermark, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Marten Rosenquist, Viveka Frykmann-Kull, Emma Svennberg, Leif Friberg
  • Publication number: 20170074892
    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20170010283
    Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 12, 2017
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser